ECHO-202/KEYNOTE-037: Phase I/II Study of Epacadostat + Pembrolizumab in Pts With Advanced RCC

June 2-6, 2017; Chicago, Illinois

Epacadostat plus pembrolizumab safe, active in patients with advanced RCC with 47% ORR in patients who received ≤ 1 previous line of therapy.

Format: Microsoft PowerPoint (.ppt)

File Size: 504 KB

Released: June 8, 2017

Acknowledgements

Supported by educational grants by

AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Cookie Settings